Arcutis to Present New Long-Term Results of ZORYVE

Arcutis Biotherapeutics (ARQT) presented new long-term data for ZORYVE cream at the 2025 RAD Conference, showing significant efficacy in treating atopic dermatitis. The Phase 3 INTEGUMENT-OLE study demonstrated that children ages 2-5 who achieved disease clearance and switched to twice-weekly ZORYVE cream 0.05% maintained disease control for a median of 238 days. By week 52, 63.1% of participants aged 2-5 years and 55.7% of those 6 years and over achieved disease clearance or almost clear status. Notable improvements in itch reduction were observed, with about half of participants achieving no or minimal itch. The treatment showed strong safety profile with low treatment-related adverse events: 2.5% in ages 2-5 and 4.7% in ages 6 and over.

https://www.stocktitan.net/news/ARQT/arcutis-to-present-new-long-term-results-of-zoryve-roflumilast-cream-58higma9t6gx.html